Posts by Anna Rodet
IFAPP TODAY – NUMBER 2, MAY 2020
The IFAPP Communication Working Group gladly shares with you the second edition of “IFAPP TODAY”, a monthly bulletin informing the global pharmaceutical medicine community of latest news. We welcome input from all member associations, individual affiliates and followers.
Read MoreXX ICPM and I SIMeF Conference
Please mark in your calendar the dates of December 2-3-4, 2020: we do hope to see many of you at the Conference Center of Sapienza University in Rome
Read MoreFirst edition of “IFAPP TODAY”
The IFAPP Communication Working Group gladly shares with you the first-ever edition of “IFAPP TODAY”, a monthly bulletin informing the global pharmaceutical medicine community of latest news. We welcome input from all member associations, individual affiliates and followers.
Read MoreIFAPP Launched a “Company Page” on LinkedIn
After a nice growth of the number of group members on LinkedIn IFAPP intends to reach out with its communications to more than the current group of 560 pharmaceutical medicine professionals. Maintaining the group status has a number of advantages, not the least that we know each other by name. It does, however, not allow…
Read MoreNew IFAPP Member Associations from Bulgaria and Turkey
On 24 March 2020 the IFAPP House of Delegates unanimously adopted the membership applications from BADI, the Bulgarian Association of Drug Information, and the Pharmaceutical Medicine Working Group of BIYILDER, the Biotechnological Drugs Society, Turkey. IFAPP extends a warm welcome and looks forward to closely cooperating with both societies.
Read MoreCOVID-19/SARS-CoV-2 Pandemic
Check out this article from the Faculty of Pharmaceutical Medicine, prepared by Dr. Penny Ward FFPM, detailing the current knowledge on SARS-CoV-2 and COVID-19 including the epidemiology of the outbreak, viral lifestyle and current treatment. https://www.fpm.org.uk/blog/covid-19-sars-cov-2-pandemic/
Read MoreIFAPP’s recommendation in combatting COVID-19
FDA statement
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic
Read MoreEMA statement
Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) Pandemic
Read MoreACRO statement
Considerations to Support Clinical Trial Monitoring Oversight During COVID-19
Read More